Avedro, Inc. today announced it has signed a conclusive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the regimen of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the stage of these degenerative disorders and the dog* decline in patient’s visual acuity.

More: - Read the rest here